Skip to content

Bile Acid Metabolism of Gut Microbiota in Patients with Hepatic Dysfunction

Bile Acid Metabolism of Gut Microbiota in Patients with Hepatic Dysfunction

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500104189
Enrollment
Unknown
Registered
2025-06-12
Start date
2025-06-16
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic Dysfunction

Interventions

Mild hepatic impairment:NA
Moderate hepatic impairment:NA
Severe hepatic impairment:NA

Sponsors

The First Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18-75 years, male or female 2) Body mass index (BMI) ranging from 18.0 to 32.0 kg/m^2 3) For subjects with hepatic dysfunction, the following criteria must be met: Hepatic dysfunction caused by pre-existing primary liver diseases, confirmed as stable (>1 month) through medical history, physical examination, laboratory tests, or imaging studies; No medication use within 4 weeks prior to screening, or for those requiring long-term treatment for hepatic dysfunction and/or other comorbidities, medication regimens should remain stable for at least 4 weeks.

Exclusion criteria

Exclusion criteria: 1) Severe infections, trauma, gastrointestinal surgery, or other major surgical procedures within 5 weeks prior to screening. 2) Use of antibiotics for 3 consecutive days or longer within the past 4 weeks. 3) Alcohol abuse. 4) Patients with any of the following conditions: Acute or chronic renal insufficiency, uremia; congenital heart disease; systemic lupus; erythematosus; Hematologic disorders (aplastic anemia, idiopathic thrombocytopenic purpura, or anemia with hemoglobin <10 g/dL); epilepsy; severe psychiatric disorders within the last 6 months; severe organic diseases (e.g., malignant tumors/cancer, coronary artery disease, myocardial infarction, stroke); infectious diseases (e.g., tuberculosis, AIDS)

Design outcomes

Primary

MeasureTime frame
Fecal metagenomics;Fecal Metagenomics;Fecal bile acids;Serum bile acids;Chile-Pugh score;

Secondary

MeasureTime frame
General Information (included personal conditions, underlying diseases, and underlying medications);

Countries

China

Contacts

Public ContactLiu Rui

The First Affiliated Hospital of Soochow University

liurui_0105@126.com+86 139 5410 8710

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026